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Disposition kinetics and urinary excretion of ceftriaxone were investigated
in healthy crossbred calves after its single intravenous administration (10 mg kg–1).
Based on kinetic parameters, an appropriate dosage regimen of ceftriaxone in
calves was calculated. The peak plasma level of ceftriaxone at 1 min was 84.0 ±
1.55 µg ml–1 which declined to 0.43 ± 0.05 µg ml–1 at 8 h. The value of elimina-
tion half-life (t1/2β), volume of distribution Vd (area) and total body clearance (ClB)
were 4.39 ± 0.63 h, 1.91 ± 0.19 L kg–1 and 0.31 ± 0.01 L kg–1 h–1, respectively.
Approximately 41 per cent of total administered drug was recovered in the urine
within 24 h of its administration. The plasma protein binding of ceftriaxone was
found to be concentration dependent with an overall mean of 38.55 per cent. The
binding capacity of ceftriaxone to plasma proteins and the dissociation rate con-
stant of protein-drug complex were 20.1 × 10–8 ± 18.4 × 10–8 mole g–1 and 1.07 ×
10–6 ± 0.52 × 10–6 mole, respectively. An appropriate intravenous dosage regimen
of ceftriaxone in cattle would be 12 mg kg–1 repeated at 24 h.
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Cephalosporin antibiotics are being increasingly employed in veterinary
medicine for the treatment of mild to severe bacterial infections. Ceftriaxone, a
third-generation cephalosporin is characterised by its excellent antibacterial activ-
ity against Gram-negative microorganisms in addition to a wide range of Gram-
positive bacteria. For the judicious use of an antibiotic, a rational dosage regimen
based on its pharmacokinetic investigation is a prerequisite. The disposition of
ceftriaxone has been extensively investigated in man (Benet and Williams, 1991),
rats (Hakim et al., 1989), mares (Gardner and Aucoin, 1994) and chickens (Junge
et al., 1994) but such data are lacking in cattle except for one report in neonatal
calves (Soback and Ziv, 1988). The purpose of this study was to investigate the
disposition kinetics, urinary excretion and in vitro plasma protein binding of ceftri-
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axone in crossbred calves. From the disposition kinetic data, recommendations
were made for the optimal dosage regimen of ceftriaxone in cattle.
The experiments were performed on ten healthy male crossbred calves (1–
1½ years of age) weighing 60–175 kg. The animal were kept under the usual
conditions. The study was conducted in two phases. In Phase I six calves were
used for the evaluation of disposition kinetics of ceftriaxone. Ceftriaxone (Zieta
Pharmaceuticals, Ahmedabad) was injected as 10 per cent solution in sterilised
distilled water at the dose rate of 10 mg kg–1 into the left jugular vein. Blood
samples were withdrawn from the contralateral jugular vein into heparinized
glass tubes at different time intervals, viz. 1, 2.5, 5, 7.5, 10, 15, 20, 30, 45, 60
and 90 min and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 h after drug administration.
Samples were centrifuged at room temperature and plasma was kept at –20 °C
until the analysis, which usually took place on the day after collection.
In Phase II, urinary excretion of ceftriaxone was investigated in 4 calves.
The dose and route of administration of the drug were the same as employed in
Phase I of the study. The animals were placed into metabolic stalls prior to the start
of the experiment. The metabolic stalls are designed in such a way that the whole
amount of urine voided by the animals is collected without contamination and
spillage. The urine samples were collected at predetermined time intervals, viz. 1,
2, 3, 6, 9, 12, 18 and 24 h after drug administration. The whole volume of urine
was measured and after filtration 10 ml urine samples were taken for analysis.
The protein binding of ceftriaxone was determined by employing the
standard equilibrium dialysing technique (Kunin et al., 1966), and the binding
capacity of plasma proteins to ceftriaxone and the dissociation rate constant of
protein-drug complex were determined as described by Pilloud (1973).
The concentration of ceftriaxone in plasma and urine was determined by
the standard microbiological cylinder cup plate bioassay technique using Sar-
cina lutea (ATCC 9341) as test organism (Simon and Yin, 1970; Arret et al.,
1971). The assay could detect 0.10 µg ml–1 of ceftriaxone.
The plasma concentration – time data for each calf were best fitted in a
three-compartment open model and the pharmacokinetic parameters were cal-
culated using the general formulas (Baggot, 1977; Gibaldi and Perrier, 1982).
The semi-logarithmic plot of plasma concentration of ceftriaxone against
time was best fitted in three compartments and hence the disposition kinetics of
ceftriaxone was calculated by a triexponential equation. However, the disposi-
tion kinetics of ceftriaxone in neonatal calves was described by a biexponential
equation (Soback and Ziv, 1988).
At 1 min of injection, the peak plasma concentration was 84.0 ± 1.55 µg ml–1,
which rapidly declined to 17.9 ± 0.95 µg ml–1 at 20 min and then gradually de-
clined to 2.61 ± 0.38 µg ml–1 at 2 h. The drug was not detected in plasma after 8 h
of administration. The pharmacokinetic parameters are summarised in Table 1.
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Mean ± SEM
121.3 ± 6.30
94.7 ± 6.83
25.0 ± 3.45
1.66 ± 0.18
15.78 ± 1.16
1.491 ± 0.18
0.172 ± 0.02
0.045 ± 0.003
0.500 ± 0.06
4.39 ± 0.63
32.63 ± 1.47
77.43 ± 14.9
0.08 ± 0.003
0.92 ± 0.003
1.91 ± 0.19
0.69 ± 0.07
0.31 ± 0.01
22.3 ± 2.68
2.31 ± 0.33
24.8 ± 3.6
6
124.2
91.5
31
1.73
19.66
1.819
0.203
0.035
0.381
3.42
30.18
51.58
0.08
0.92
1.63
0.57
0.33
19.3
1.71
19.2
5
113.1
77
34.8
1.25
15.29
1.744
0.097
0.045
0.398
7.17
37.91
145.39
0.09
0.91
2.73
0.01
0.26
29.8
3.84
40.3
4
150.7
126.2
23.1
1.39
17.94
1.244
0.133
0.039
0.557
5.2
36
93.28
0.07
0.93
2.08
0.72
0.28
30.4
2.59
29.4
3
119.2
87.2
30.5
1.48
16.34
2.033
0.183
0.042
0.341
3.79
28.44
52.02
0.08
0.92
1.92
0.64
0.35
21.9
1.83
21.4
2
112.6
96.5
13.6
2.51
13.66
0.971
0.232
0.051
0.714
2.99
31.89
60.39
0.09
0.91
1.35
0.59
0.31
14.2
1.89
16.8
Calf number
1
108.2
89.5
17
1.59
11.82
1.113
0.182
0.059
0.611
3.8
31.35
61.93
0.09
0.91
1.75
0.63
0.32
17.9
1.98
21.5
Unit
µg ml–1
µg ml–1
µg ml–1
µg ml–1
h–1
h–1
h–1
h
h
h
µg ml–1h
µg ml–1h2
L kg–1
L kg–1
L kg–1
L kg–1
L kg–1h–1
ratio
h
h
Table 1
Disposition kinetic parameters of ceftriaxone in calves following a single intravenous dose of 10 mg kg–1 body weight
Pharmacokinetic
parameter
Cp°
A1
A2
B
α1
α2
β
t1/2α1
t1/2α2
t1/2β
AUC
AUMC
VC
VT
Vd (area)
Vd (ss)
C1B
T/P
MRT
td
Cp° = plasma drug concentration at zero time; A1, A2 and B = zero time plasma drug concentration intercepts of regression lines of distribution phases I, II, and elimination
phase, respectively; α1, α2 = rate constants of distribution phases I and II, respectively; β = elimination rate constant; t1/2α1, t1/2α2= half lives of distribution phases I and II,
respectively; t1/2β = elimination half-life; AUC = area under the plasma concentration - time curve; AUMC = area under the first moment of plasma concentration - time
curve; Vc = volume of central compartment; VT = volume of tissue compartment; Vd (area) = apparent volume of distribution; Vd (SS) = steady-state volume of distribution;
C1B = total body clearance; T/P = tissue/plasma ratio; MRT = mean residence time; td = total duration of pharmacological effect
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The high value of the distribution rate constant α1 (15.78 h–1) indicates rapid trans-
fer of drug from central to peripheral compartment I. The low value of α2 (1.49 h–1)
indicates gradual transfer of drug to peripheral compartment II. The calculated vol-
ume of distribution (1.91 ± 0.19 L kg–1) indicates an extensive penetration of the drug
into various body tissues and fluids. The high value of the T/P ratio further confirmed
the extensive penetration of ceftriaxone into body tissues and fluids.
The elimination half-life of ceftriaxone in healthy calves calculated in the
present study was 4.39 ± 0.63 h which is considerably longer than that found in
mares (Gardner and Aucoin, 1994), rats (Hakim et al., 1989) and neonatal calves
(Soback and Ziv, 1988). The t1/2β value of ceftriaxone after intravenous admini-
stration in mares, rats and neonatal calves was calculated to be 0.81 ± 0.16 h,
0.48 h and 1.4 ± 0.6 h, respectively. Ceftriaxone has a very long elimination
half-life of 7.3 ± 1.6 h in human beings (Benet and Williams, 1991).
Table 2 summarises the data on urinary excretion of ceftriaxone after its
single intravenous administration. The highest drug concentration was obtained
within 2 h and about 41 per cent of the total administered drug was recovered in
the urine within 24 h. A rapid urinary excretion has also been reported in neo-
natal calves (Soback and Ziv, 1988) and in man (Benet and Williams, 1991).
Table 2
Urinary excretion of ceftriaxone in calves following a single intravenous dose
of 10 mg kg–1 body weight
Time interval
(h)
Urinary drug concentrations
(µg ml–1)
Extent of excretion
(% of total dose)
0–1 422.2 ± 164.4 14.3 ± 7.8
1–2 711.7 ± 135.2 14.4 ± 3.34
2–3 305.6a 7.92
3–6 427.6 ± 122.5 14.8 ± 2.74
6–9 126.1 ± 29.2 2.27 ± 0.64
9–12 14.7 ± 5.43 0.34 ± 0.11
12–18 28.8 ± 6.71 0.91 ± 0.35
18–24 0.95 ± 0.16 0.07 ± 0.03
Total 41.4 ± 1.69
avalue of a single animal
Table 3 shows the in vitro plasma protein binding of ceftriaxone at different
concentrations. The extent of protein binding varied from 11.9 to 71.1 per cent
with a mean of 38.6 per cent. The results on plasma protein binding of ceftriaxone
revealed that the extent of binding is inversely proportional to the plasma concen-
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tration. The results of the present investigation agree with those of Popick et al.
(1987) and Hakim et al. (1989) who reported that the protein binding of ceftriax-
one was concentration dependent in rats, baboons, human beings and rabbits. In
rats, ceftriaxone was highly bound (approximately 90–95%) at low plasma con-
centrations (< 10 µg ml–1) but considerably less binding (approximately 60%) was
obtained at high plasma concentrations (> 400 µg ml–1).
Table 3
In vitro binding of ceftriaxone to plasma proteins of calves
Extent of binding (%)
Concentration of ceftriaxone (µg ml–1) βi Kβ
2 5 10 25 50 75 (mole g–1) (mole)
1 53.0 68.2 42.9 30.4 16.2 8.72 1.95 × 10–8 1.06 × 10–6
2 56.5 73.8 34.5 45.96 23.8 11.6 1.42 × 10–8 1.97 × 10–6
3 51.0 71.4 32.2 38.88 19.5 15.3 57.0 × 10–8 0.17 × 10–6
Mean 53.5 71.1 36.5 38.4 19.8 11.9 20.1 × 10–8 1.07 × 10–6
± SEM ± 1.61 ± 0.58 ± 3.25 ± 4.50 ± 2.21 ± 1.90 ± 18.4 × 10–8 ± 0.52 × 10–6
The capacity of calf plasma proteins to bind ceftriaxone (βi) and the dis-
sociation rate constant of protein-drug complex (Kβ) were also determined. In
three different experiments the value of βi and Kβ of ceftriaxone were calculated
to be 20.1 × 10–8 ± 18.4 × 10–8 mole g–1 and 1.07 × 10–6 ± 0.52 × 10–6 mole, re-
spectively.
Based on these results, to maintain the minimum therapeutic plasma con-
centration of 0.1 µg/ml (Soback and Ziv, 1988), the most appropriate dosage
regimen of ceftriaxone in cattle was calculated to be 12 mg kg–1 repeated at 24 h
intervals. Since cephalosporins are primarily excreted by the kidney, the dosage
should be reduced in cases of renal insufficiency.
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